Article

AMD-therapy developer plans to sell stock

Mississauga, Ontario-OccuLogix, an ophthalmic therapeutic company working on treatments for age-related macular degeneration (AMD), plans to hold an initial public offering of its stock.

Mississauga, Ontario-OccuLogix, an ophthalmic therapeutic company working on treatments for age-related macular degeneration (AMD), plans to hold an initial public offering of its stock.

The company, formerly Vascular Sciences, and TLC Vision, its major shareholder, said it would file a registration statement with the SEC. Copies of the prospectus will be available from Citigroup Global Markets Inc.

Founded in 1996, OccuLogix is working on a variety of innovative treatments for eye disease, including rheopheresis, a filtering process designed to slow the progression of dry AMD by removing certain compounds in the blood. The business is valued at a total $350 million to $560 million, or $5 to $8 per TLC share.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.